At a glance
- Originator Aventis
- Class Anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors; Dinoprostone receptor antagonists; Lipoxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Skin disorders
Most Recent Events
- 02 Jul 2004 Discontinued - Preclinical for Skin disorders in European Union (Topical)
- 02 Jul 2004 Discontinued - Preclinical for Skin disorders in USA (Topical)
- 22 Dec 1999 Hoechst Marion Roussel has merged with Rhône-Poulenc Rorer to form Aventis Pharma